Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016
Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma was presented on poster P281 at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.
The poster is entitled ‘Final Phase 2 Study Data of Melflufen and Dexamethasone for patients with Relapsed-Refractory Multiple Myeloma’ and can be downloaded here.
CEO, Jakob Lindberg commented “The results to date support our belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.
Multiple myeloma is the second most common hematological cancer and in 2016, it is estimated that in the US there will be 30,330 new cases of myeloma and an estimated 12,650 people will die of this disease1. In 95% of cases the patient’s cancer has metastasized, which today, has a five-year survival rate of 47.4%1.
Oncopeptides is a clinical stage pharmaceutical company developing oncology therapies centered around peptidase targeting.
Melflufen, Oncopeptides lead compound in clinical development, is a peptidase targeted therapy and a potent anti-angiogenetic compound. It triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA.
Many peptidases that are overexpressed in cancer cells, such as tumor cells in multiple myeloma, cleave melflufen so that the concentration of active compound increases in the malignant target cell. This is excepted to result in targeted delivery of the molecule and better treatment of the disease.
Oncopeptides is currently in the closing stages of a Phase II clinical trial with melflufen in patients with relapsed and relapsed-refractory multiple myeloma. The study is being carried out across six centers; in Denmark, Italy, the Netherlands, Sweden, and the US (two centers) – with Dana Faber Cancer Institute, Boston, MA being the lead investigator site.